The first survey results reveal physicians seek new diagnostic tools and insights to improve COVID-19 management and patient outcomes OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth
OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the start of a collaboration with Valneva. The Company will perform T cell testing on participants
PerkinElmer to acquire Oxford Immunotec for USD 22.00 per share in cash Transaction expected to be completed in the first half of 2021 WALTHAM, Mass. & LONDON --(BUSINESS WIRE)--Jan. 7, 2021-- PerkinElmer, Inc. (NYSE: PKI) (“ PerkinElmer ”) and Oxford Immunotec Global PLC (NASDAQ: OXFD) (" Oxford
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, announce the formation and initial meeting of the Global T cell expert consortium (GTEC).
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announced that the Company’s T-Cell Select reagent kit has been approved for use by the Ministry of Food and
OXFORD, United Kingdom and MARLBOROUGH, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company today announces it has entered into an exclusive distribution agreement with RIKEN Genesis Co., Ltd, a subsidiary of
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to hold a virtual investor event on Thursday, December 17, 2020. Dr.
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a global, high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration
If approved, the T-Cell Select reagent kit would enable automated sample preparation and the T-SPOT ® .TB test to be used with blood samples stored for up to 54 hours at room temperature OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC
Third quarter revenue of $ 19.4 million, above guidance of range of $18 - $ 19 million Asia-Pacific region returns to g r owth and sets a new quarterly sales record for the region Europe & rest of world and U.S. regions recover strongly from low point in the second quarter Gross Margin of 76.4%